Insider Buying: BioSig Technologies Inc (BSGM) CEO Acquires 6,000 Shares of Stock

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth L. Londoner acquired 6,000 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $6.88 per share, for a total transaction of $41,280.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

BSGM stock opened at $6.87 on Monday. BioSig Technologies Inc has a 52 week low of $3.50 and a 52 week high of $9.97. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.99 and a quick ratio of 10.99.

BioSig Technologies (NASDAQ:BSGM) last released its quarterly earnings results on Monday, April 15th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Analysts forecast that BioSig Technologies Inc will post -1.17 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of BioSig Technologies during the 4th quarter worth about $48,000. Deutsche Bank AG bought a new stake in shares of BioSig Technologies during the 4th quarter worth about $58,000. Morgan Stanley raised its position in shares of BioSig Technologies by 212.1% during the 1st quarter. Morgan Stanley now owns 11,547 shares of the company’s stock worth $71,000 after buying an additional 7,847 shares in the last quarter. Northern Trust Corp bought a new stake in shares of BioSig Technologies during the 1st quarter worth about $80,000. Finally, BlackRock Inc. bought a new stake in shares of BioSig Technologies during the 1st quarter worth about $365,000. Institutional investors own 5.05% of the company’s stock.

BSGM has been the topic of several recent research reports. Laidlaw set a $11.00 price objective on shares of BioSig Technologies and gave the company a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research downgraded shares of BioSig Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th.

COPYRIGHT VIOLATION NOTICE: This news story was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/27/insider-buying-biosig-technologies-inc-bsgm-ceo-acquires-6000-shares-of-stock.html.

About BioSig Technologies

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Featured Article: Cost of Goods Sold (COGS)

Insider Buying and Selling by Quarter for BioSig Technologies (NASDAQ:BSGM)

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.